Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard
Vivos Therapeutics received a Nasdaq Staff letter dated October 20, 2026 confirming it currently complies with Listing Rule 5550(b)(1), the $2.5 million minimum stockholders' equity standard. Compliance was restored via the closing of a transaction with SOD Sciences, in which Vivos issued 12,000 shares of Series C Convertible Preferred Stock with $12 million aggregate stated value, expected to boost equity by more than $10 million. The relief is conditional: if compliance is not demonstrated again at the next periodic report, Vivos faces potential delisting.
Key figures
- Series c stated value
- 12000000
- Sod equity interest pct
- 11%
- Expected equity increase
- $10 million+
- Series c conversion price
- 0.15
- Series c underlying common shares
- 80000000
- Minimum stockholders equity required
- 2500000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.